GID BIO Completes Enrollment for Cell Therapy Study

GID BIO completed enrollment for the first of two pivotal Phase III studies to investigate the use of a patient’s own stromal vascular fraction cells to treat knee osteoarthritis (OA). The clinical study involves a cellular therapeutic approach delivered in an outpatient setting that takes less than three hours.

The Phase III study was...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us